Abstract:Alterations in cell signaling pathways drive cancer progression. Such changes can be detected by transcriptomics and proteomics profiling of tumor samples. Although proteomics profiling captures these alterations more directly, RNA-seq transcriptomics remains the most widely available and cost-effective source of data for elucidating tumor-specific cell signaling mechanisms. The eXpression2Kinases (X2K) pipeline is a computational workflow that starts with differentially expressed mRNAs, the identified differentially expressed genes are then used as input for transcription factor enrichment analysis. Then, the top-ranked transcription factors are connected via additional protein-protein interactions from several databases. Finally, the top-ranked transcription factors and the proteins that directly interact and connect these factors are subjected to kinase enrichment analysis. Such analysis identifies protein kinases most likely responsible for the observed changes in gene expression. The X2K pipeline can be applied to analyze tumor-specific transcriptomics to infer upstream regulatory transcription factors, protein intermediates, and kinases that are likely the drivers of cancer progression. While the X2K pipeline infers regulatory pathways from transcriptomics alone, phosphoproteomics can be used to independently validate the inferred kinases, and to calibrate the parameters of the X2K pipeline. Furthermore, this multiomics approach predicts cell signaling pathways with multiple layers of evidence by linking changes observed in the phosphoproteome to changes observed in the transcriptome. Here, we used the transcriptomics and phosphoproteomics profiles from the Clinical Proteomic Tumor Analysis Consortium (CPTAC) pan-cancer dataset, including 1,020 samples across 10 different cancer types, to optimize the parameters of the X2K pipeline and predict pan-cancer as well as tumor-specific signaling pathways. While inferred pathways were distinct between different tumor types, we observed global enrichment of receptor tyrosine kinases and cell cycle kinases. These pathways were subsequently tested for association with patient survival to identify pathways that may be effective therapeutic targets, for example, PTK2 signaling was identified for many lung cancer tumors (LUAD and LSCC) as well as some breast, head & neck squamous. Altogether, the X2K pipeline presents a rational approach to better identify driver regulatory mechanisms from patient-specific profiling of tumors with both transcriptomics and phosphoproteomics. Citation Format: Eden Z. Deng, Giacomo B. Marino, Daniel J. Clarke, Weiping Ma, Pei Wang, Avi Ma'ayan. Optimizing pan-cancer driver pathway analysis from patient transcriptomics and phosphoproteomics [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7346.

Individualized pathway activity algorithm identifies oncogenic pathways in pan-cancer analysis

Pathway-Based Personalized Analysis of Pan-Cancer Transcriptomic Data

Revealing Prognosis-Related Pathways at the Individual Level by a Comprehensive Analysis of Different Cancer Transcription Data.

Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data

Abstract 7346: Optimizing pan-cancer driver pathway analysis from patient transcriptomics and phosphoproteomics

Analysis of Whole Genomic Expression Profiles and Screening of the Key Signaling Pathways Associated with Pancreatic Cancer.

Identifying individualized risk subpathways reveals pan-cancer molecular classification based on multi-omics data

SEPA: Signaling Entropy-Based Algorithm to Evaluate Personalized Pathway Activation for Survival Analysis on Pan-Cancer Data.

Towards Pathway-Centric Cancer Therapies Via Pharmacogenomic Profiling Analysis of Erk Signalling Pathway

Identifying Cancer Specific Signaling Pathways Based on the Dysregulation Between Genes

Oncogenic signaling pathway dysregulation landscape reveals the role of pathways at multiple omics levels in pan-cancer

Analysis of Pathway Activity in Primary Tumors and NCI60 Cell Lines Using Gene Expression Profiling Data.

Prognostic Pathways Guide Drug Indications in Pan-Cancers

Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer.

Identification and Functional Analysis of Individual-Specific Subpathways in Lung Adenocarcinoma

Pan-Cancer Identification of Prognostic-Associated Metabolic Pathways

PathDriver: Cancer Driver Genes Identification Based on the Metabolic Pathway

A novel dysregulated pathway-identification analysis based on global influence of within-pathway effects and crosstalk between pathways.

Pathway Activation Analysis for Pan-Cancer Personalized Characterization Based on Riemannian Manifold

Unbiased discovery of cancer pathways and therapeutics using Pathway Ensemble Tool and Benchmark

Pathway-based analysis of breast cancer.